Advertisement
Canada markets close in 1 hour 44 minutes
  • S&P/TSX

    21,862.94
    -148.78 (-0.68%)
     
  • S&P 500

    5,068.42
    -2.13 (-0.04%)
     
  • DOW

    38,458.13
    -45.56 (-0.12%)
     
  • CAD/USD

    0.7295
    -0.0025 (-0.34%)
     
  • CRUDE OIL

    82.63
    -0.73 (-0.88%)
     
  • Bitcoin CAD

    88,710.73
    -2,818.85 (-3.08%)
     
  • CMC Crypto 200

    1,401.43
    -22.67 (-1.59%)
     
  • GOLD FUTURES

    2,336.70
    -5.40 (-0.23%)
     
  • RUSSELL 2000

    1,995.18
    -7.46 (-0.37%)
     
  • 10-Yr Bond

    4.6560
    +0.0580 (+1.26%)
     
  • NASDAQ

    15,706.40
    +9.76 (+0.06%)
     
  • VOLATILITY

    15.74
    +0.05 (+0.32%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6821
    -0.0015 (-0.22%)
     

Travere: 4Q Earnings Snapshot

SAN DIEGO (AP) _ Travere Therapeutics, Inc. (TVTX) on Monday reported a loss of $121.6 million in its fourth quarter.

On a per-share basis, the San Diego-based company said it had a loss of $2.37.

The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 43 cents per share.

The drug developer posted revenue of $51 million in the period, also missing Street forecasts. Three analysts surveyed by Zacks expected $51.3 million.

For the year, the company reported that its loss widened to $169.4 million, or $3.56 per share. Revenue was reported as $198.3 million.

ADVERTISEMENT

Travere shares have climbed 12% since the beginning of the year. In the final minutes of trading on Monday, shares hit $30.56, more than doubling in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TVTX at https://www.zacks.com/ap/TVTX